Prof. Dr. Öznur BAL

1. Clinicopathological Features of Intrahepatic Cholangiocarcinoma with Assessment of IDH1 Mutation: A Two-Center Retrospective Study

Buyukaksoy M., Akturk Esen S., TURHAN N., Sahiner E. S., EROĞLU İ., Sert A., et al.

Journal of Clinical Medicine , cilt.15, sa.13, 2026 (SCI-Expanded, Scopus)

2. Abiraterone Acetate Plus Prednisone Induced Bilateral Avascular Necrosis of the Femoral Head

Sekmek S., ÖZKURT B., Mehtiyev M., BAL Ö., ALGIN E.

Journal of Oncological Science , cilt.12, sa.1, ss.94-97, 2026 (Scopus, TRDizin)

3. Efficacy of Anti-VEGF and Anti-EGFRs in Microsatellite Instable (MSI-H) Metastatic Colorectal Cancer in a Turkish Oncology Group (TOG) Cohort Study †

Deliktaş Onur İ., DOĞAN M., Öztürk M. A., ŞAHİN T. K., Kiracı M., Arslan A. M., et al.

Current Oncology , cilt.32, sa.11, 2025 (SCI-Expanded, Scopus)

4. Real-world efficacy and safety data of immune checkpoint inhibitors in Turkish patients with metastatic melanoma: A Turkish oncology group retrospective study

Ozgun A., Mustafayev F. N. A., Dogan I., Vatansever S., Eryilmaz M. K., ERDOĞAN A. P., et al.

Molecular and Clinical Oncology , cilt.22, sa.6, 2025 (ESCI, Scopus)

5. A New Prognostic Indicator for Biliary Tract Cancers: The ABIC Score

Bayram D., BAL Ö., Karaman K., Bardakçı M., Demirtaş Esmer D., Seven İ., et al.

Current Oncology , cilt.32, sa.4, 2025 (SCI-Expanded, Scopus)

6. Refractory hypoglycemia is sensitive to octreotide therapy: is it triggered by sorafenib or hepatocellular carcinoma?

Çakmak M., BAL Ö., Kiraci M., Topaloǧlu O., KÖŞ F. T., ALGIN E.

Anti-Cancer Drugs , cilt.36, sa.2, ss.140-142, 2025 (SCI-Expanded, Scopus)

7. Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study

Yildirim H. C., Kapar C., Koksal B., Seyyar M., Sanci P. C., Guliyev M., et al.

Journal of Chemotherapy , cilt.37, sa.1, ss.69-75, 2025 (SCI-Expanded, Scopus)

8. The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer

Ceylan F., Efil S. C., Şener Dede D., Tenekeci A. K., Bilgin B., Yücel Ş., et al.

Expert Review of Anticancer Therapy , cilt.25, sa.5, ss.579-588, 2025 (SCI-Expanded, Scopus)

9. Clinical features and prognostic factors in thymoma and thymic carcinoma

Bayram D., Sekmek S., Kayaalp M., Bardakçı M., Hafızoğlu E., Uçar G., et al.

Indian Journal of Thoracic and Cardiovascular Surgery , cilt.40, sa.6, ss.660-668, 2024 (ESCI, Scopus)

10. Impact of 68Ga-PSMA PET/CT on Survival and Management in Prostate Cancer

ALGIN E., Okudan B., Açıkgöz Y., Sayan H., BAL Ö., Seven B.

Current Medical Imaging , cilt.20, 2024 (SCI-Expanded, Scopus)

11. The Prognostic and Functional Impact of Sprouty 2 Expression in Non-small Cell Lung Cancer

Acikgoz Y., Yildirim F. U., Esen S. A., Ucar G., Ergun Y., BAL Ö., et al.

American Journal of Clinical Oncology: Cancer Clinical Trials , cilt.46, sa.12, ss.543-550, 2023 (SCI-Expanded, Scopus)

12. The effectiveness of adjuvant treatment approaches for resectable esophageal cancer: A single-center experience

ALGIN E., Esen S. A., Acikgoz Y., BAL Ö.

Journal of Cancer Research and Therapeutics , cilt.19, sa.7, ss.2018-2024, 2023 (SCI-Expanded, Scopus)

13. Treatment Outcomes and Prognostic Factors in N3 Stage Gastric Cancer After Curative Resection: A Real World Data

YILDIRIM C., Acikgoz Y., Ergun Y., ALGIN E., BAL Ö.

Cancer Management and Research , cilt.15, ss.1085-1096, 2023 (SCI-Expanded, Scopus)

14. Unresectable Hepatocellular Carcinoma and Prognostic Factors of Sorafenib Treatment: A Real-Life Experience

Erol C., Bardakçi M., Hizal M., Kahraman S., YEKEDÜZ E., GÜVEN D. C., et al.

Journal of Oncological Science , cilt.9, sa.2, ss.72-78, 2023 (Scopus, TRDizin)

15. “Swords and Shields” against COVID-19 for patients with cancer at “clean” and “pandemic” hospitals: are we ready for the second wave?

Karacin C., Acar R., BAL Ö., EREN T., ŞENDUR M. A. N., Acikgoz Y., et al.

Supportive Care in Cancer , cilt.29, sa.8, ss.4587-4593, 2021 (SCI-Expanded, Scopus)

16. The evaluation of the role of BMi and insulin resistance on inflammatory markers, PAI-1 levels and arterial stiffness in newly diagnosed type 2 diabetes mellitus patients

KOCA N., AYAR K., BAL Ö., ERSOY C.

Minerva Endocrinology , cilt.46, sa.1, ss.116-123, 2021 (SCI-Expanded, Scopus)

17. Is there any clinical or laboratory predictive factor for cetuximab-induced skin toxicity?

Acikgoz Y., BAL Ö., Ucar G., Durnali A., Ergun Y., Dirikoc M., et al.

Expert Opinion on Drug Safety , cilt.20, sa.5, ss.611-621, 2021 (SCI-Expanded, Scopus)

18. Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience

Bahçeci A., PAYDAŞ S., AK N., Ferhatoğlu F., SAİP P. M., SEYDAOĞLU G., et al.

Cancer Investigation , cilt.39, sa.6-7, ss.473-481, 2021 (SCI-Expanded, Scopus)

19. Albumin-To-Alkaline Phosphatase Ratio: Does It Predict Survival in Grade 1 and Grade 2 Neuroendocrine Tumors?

Acikgoz Y., BAL Ö., DOĞAN M.

Pancreas , cilt.50, sa.1, ss.111-117, 2021 (SCI-Expanded, Scopus)

20. The prognostic value of tumor/lymph node standardized uptake value max ratio and correlation with hematologic parameters in stage III nonsmall cell lung cancer

Açikgoz Y., GÜRLER F., Inci B. K., Ergun Y., Ucar G., Dirikoc M., et al.

Medicine (United States) , cilt.99, sa.48, 2020 (SCI-Expanded, Scopus)

Prof. Dr. Öznur BAL

Yayınlar & Eserler

1. Clinicopathological Features of Intrahepatic Cholangiocarcinoma with Assessment of IDH1 Mutation: A Two-Center Retrospective Study

2. Abiraterone Acetate Plus Prednisone Induced Bilateral Avascular Necrosis of the Femoral Head

3. Efficacy of Anti-VEGF and Anti-EGFRs in Microsatellite Instable (MSI-H) Metastatic Colorectal Cancer in a Turkish Oncology Group (TOG) Cohort Study †

4. Real-world efficacy and safety data of immune checkpoint inhibitors in Turkish patients with metastatic melanoma: A Turkish oncology group retrospective study

5. A New Prognostic Indicator for Biliary Tract Cancers: The ABIC Score

6. Refractory hypoglycemia is sensitive to octreotide therapy: is it triggered by sorafenib or hepatocellular carcinoma?

7. Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study

8. The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer

9. Clinical features and prognostic factors in thymoma and thymic carcinoma

10. Impact of 68Ga-PSMA PET/CT on Survival and Management in Prostate Cancer

11. The Prognostic and Functional Impact of Sprouty 2 Expression in Non-small Cell Lung Cancer

12. The effectiveness of adjuvant treatment approaches for resectable esophageal cancer: A single-center experience

13. Treatment Outcomes and Prognostic Factors in N3 Stage Gastric Cancer After Curative Resection: A Real World Data

14. Unresectable Hepatocellular Carcinoma and Prognostic Factors of Sorafenib Treatment: A Real-Life Experience

15. “Swords and Shields” against COVID-19 for patients with cancer at “clean” and “pandemic” hospitals: are we ready for the second wave?

16. The evaluation of the role of BMi and insulin resistance on inflammatory markers, PAI-1 levels and arterial stiffness in newly diagnosed type 2 diabetes mellitus patients

17. Is there any clinical or laboratory predictive factor for cetuximab-induced skin toxicity?

18. Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience

19. Albumin-To-Alkaline Phosphatase Ratio: Does It Predict Survival in Grade 1 and Grade 2 Neuroendocrine Tumors?

20. The prognostic value of tumor/lymph node standardized uptake value max ratio and correlation with hematologic parameters in stage III nonsmall cell lung cancer

Yayın

Yayın (WoS)

Yayın (Scopus)

H-İndeks (WoS)

Atıf (Scopus)

H-İndeks (Scopus)

Proje

Tez Danışmanlığı

Açık Erişim